CRF01_AE-Specific Neutralizing Activity Observed in Plasma Derived from HIV-1-Infected Thai Patients Residing in Northern Thailand: Comparison of Neutralizing Breadth and Potency between Plasma Derived from Rapid and Slow Progressors

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Sapsutthipas, Sompong ^a   Tsuchiya, Naho ^b   Pathipavanich, Panita ^c   Ariyoshi, Koya ^b   Sawanpanyalert, Pathom ^d   Takeda, Naokazu ^a,e   Isarangkura na ayuthaya, Panasda ^d   Kameoka, Masanori ^a,e,f  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b NAGASAKI UNIVERSITY   (Japan)

^c LAMPANG HOSPITAL   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e OSAKA UNIVERSITY   (Japan)

^f KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PLASMA; THAILAND; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CROSS REACTIONS; DISEASE PROGRESSION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; REASSORTANT VIRUSES; THAILAND;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872126404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053920     Document Type: Article

References (32)

1. Girard MP, Osmanov S, Assossou OM, Kieny MP, (2011) Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29: 6191-6218.
2. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, et al. (2010) Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS ONE 5: e13916.
3. Barbas CF 3rd, Collet TA, Amberg W, Roben P, Binley JM, et al (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230: 812-823.
4. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of virology 70: 1100-1108.
5. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS research and human retroviruses 17: 1757-1765.
6. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 10: 1651-1658.
7. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
8. Wu X, Yang ZY, Li Y, Hogerkorp CM, (2010) Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
9. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
10. Arroyo MA, Phanuphak N, Krasaesub S, Sirivichayakul S, Assawadarachai V, et al. (2010) HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses 26: 5-12.
11. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, et al. (2009) Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect 11: 334-343.
12. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, et al. (2009) Genotypic Characterization of CRF01_AE env Genes Derived from Human Immunodeficiency Virus Type 1-Infected Patients Residing in Central Thailand. AIDS Res Hum Retroviruses 25: 229-236.
13. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, et al. (1997) Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71: 7478-7487.
14. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
15. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
16. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
17. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
18. Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, et al. (2005) Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol 79: 5996-6004.
19. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, et al. (1997) Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. The Journal of infectious diseases 176: 924-932.
20. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, et al. (1996) Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. The Journal of infectious diseases 173: 60-67.
21. Cao Y, Qin L, Zhang L, Safrit J, Ho DD, (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. The New England journal of medicine 332: 201-208.
22. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84: 1631-1636.
23. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, et al. (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83: 188-199.
24. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, et al. (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83: 10269-10274.
25. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348.
26. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769.
27. Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, et al. (2012) Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity. Journal of virology 86: 2045-2055.
28. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. (2011) The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection. Journal of virology 85: 4828-4840.
29. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, et al. (1996) Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Research and Human Retroviruses 12: 1319-1328.
30. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
31. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81: 4886-4891.
32. Boonchawalit S, Jullaksorn D, Uttiyoung J, Yowang A, Krathong N, et al. (2011) Molecular Evolution of HIV-1 CRF01_AE Env in Thai Patients. PLoS ONE 6: e27098.